NWM
CPRX

Nova Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Nova Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$1.97K – 585
2025
Q3 		$1.97K Buy
+100
New +$2.06K ﹤0.01% 511

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nova Wealth Management's CPRX Position: Q4 2025 in Review

Nova Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 100 shares — an estimated $1.97K sold.

Nova Wealth Management first reported a position in CPRX in Q3 2025 and held it in 1 quarter. The position peaked at $1.97K in Q3 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Nova Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Nova Wealth Management sold 100 Catalyst Pharmaceutical shares in Q4 2025, an estimated $1.97K.
  • Nova Wealth Management first reported a position in Catalyst Pharmaceutical in Q3 2025 and held it in 1 quarter.
  • Nova Wealth Management's Catalyst Pharmaceutical position peaked at $1.97K in Q3 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Nova Wealth Management's 13F filing for Q4 2025, filed 14 Jan 2026.